Brigham & Women's Hospital, Boston, MA.
Harvard Medical School, Boston, MA.
AMIA Annu Symp Proc. 2024 Jan 11;2023:339-348. eCollection 2023.
Venous Thromboembolism (VTE) is a serious, preventable public health problem that requires timely treatment. Because signs and symptoms are non-specific, patients often present to primary care providers with VTE symptoms prior to diagnosis. Today there are no federal measurement tools in place to track delayed diagnosis of VTE. We developed and tested an electronic clinical quality measure (eCQM) to quantify Diagnostic Delay of Venous Thromboembolism (DOVE); the rate of avoidable delayed VTE events occurring in patients with a VTE who had reported VTE symptoms in primary care within 30 days of diagnosis. DOVE uses routinely collected EHR data without contributing to documentation burden. DOVE was tested in two geographically distant healthcare systems. Overall DOVE rates were 72.60% (site 1) and 77.14% (site 2). This novel, data-driven eCQM could inform healthcare providers and facilities about opportunities to improve care, strengthen incentives for quality improvement, and ultimately improve patient safety.
静脉血栓栓塞症(VTE)是一个严重的、可预防的公共卫生问题,需要及时治疗。由于症状不具有特异性,患者在确诊前通常会向初级保健提供者报告 VTE 症状。目前,尚无用于跟踪 VTE 诊断延迟的联邦衡量工具。我们开发并测试了一种电子临床质量衡量标准(eCQM),以量化静脉血栓栓塞症的诊断延迟(DOVE);在诊断后 30 天内报告初级保健中有 VTE 症状的 VTE 患者中,可避免的 VTE 事件的发生率。DOVE 使用常规收集的 EHR 数据,不会增加文档负担。DOVE 在两个地理位置不同的医疗保健系统中进行了测试。总体 DOVE 发生率分别为 72.60%(站点 1)和 77.14%(站点 2)。这种新颖的数据驱动型 eCQM 可以为医疗保健提供者和医疗机构提供有关改善护理机会的信息,加强质量改进激励措施,并最终提高患者安全性。